HC Wainwright Weighs in on Cartesian Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on Tuesday, April 23rd. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($0.47) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.52) EPS and Q4 2025 earnings at ($0.58) EPS.

RNAC has been the subject of a number of other reports. Leerink Partnrs reaffirmed an “outperform” rating on shares of Cartesian Therapeutics in a research note on Tuesday. SVB Leerink assumed coverage on shares of Cartesian Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $39.00 target price on the stock. Finally, Needham & Company LLC assumed coverage on shares of Cartesian Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $42.00 target price on the stock.

Cartesian Therapeutics Stock Up 0.9 %

Shares of NASDAQ:RNAC opened at $20.90 on Wednesday. The stock has a 50 day moving average of $19.26. Cartesian Therapeutics has a twelve month low of $11.66 and a twelve month high of $42.60.

Cartesian Therapeutics (NASDAQ:RNAC) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($2.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($2.10). The company had revenue of $8.27 million during the quarter. Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%.

Insider Buying and Selling

In other news, Director Timothy A. Springer purchased 21,612 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were acquired at an average price of $16.20 per share, for a total transaction of $350,114.40. Following the completion of the acquisition, the director now directly owns 1,017,228 shares of the company’s stock, valued at $16,479,093.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired 22,472 shares of company stock worth $365,981 in the last ninety days. 31.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cartesian Therapeutics

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee acquired a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned 0.98% of Cartesian Therapeutics as of its most recent filing with the SEC. 86.95% of the stock is currently owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.